• +1-646-491-9876
    • +91-20-67278686

    Search

    Intermittent Claudication - Pipeline Review, H1 2017

    Intermittent Claudication - Pipeline Review, H1 2017

    • Report Code ID: RW0001689423
    • Category Healthcare
    • No. of Pages 48
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Intermittent Claudication - Pipeline Review, H1 2017, provides an overview of the Intermittent Claudication (Cardiovascular) pipeline landscape.

    Intermittent claudication is caused by narrowing or blockage in the main artery that takes blood to leg. Symptoms include burning or tingling sensation, decreased or absent pulse in the lower limb, pale or bluish skin, poor hair growth on the legs and sores or wounds on the lower limb that heal slowly, poorly. Risk factors include smoking, high cholesterol, high blood pressure, obesity, diabetes, age and family history.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Intermittent Claudication - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Intermittent Claudication (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Intermittent Claudication (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Discovery stages are 1, 4 and 1 respectively.

    Intermittent Claudication (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Intermittent Claudication (Cardiovascular).
    - The pipeline guide reviews pipeline therapeutics for Intermittent Claudication (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Intermittent Claudication (Cardiovascular) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Intermittent Claudication (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Intermittent Claudication (Cardiovascular)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Intermittent Claudication (Cardiovascular).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Intermittent Claudication (Cardiovascular) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Intermittent Claudication - Overview
    Intermittent Claudication - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Intermittent Claudication - Companies Involved in Therapeutics Development
    Genovate Biotechnology Co LTD
    ID Pharma Co Ltd
    Kowa Company Ltd
    Nuo Therapeutics Inc
    Pluristem Therapeutics Inc
    Intermittent Claudication - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Intermittent Claudication - Drug Profiles
    ALD-301 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cilostazol CR - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    DVC-10101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    K-134 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LT-2003 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PLX-PAD - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Intermittent Claudication - Dormant Projects
    Intermittent Claudication - Discontinued Products
    Intermittent Claudication - Product Development Milestones
    Featured News & Press Releases
    Jan 12, 2017: Pluristem Completes Patient Enrollment in a Large Multinational Phase II Trial in Intermittent Claudication
    May 16, 2016: Pluristem Completes Enrollment of 150 Patients in Phase II Intermittent Claudication Trial
    Aug 17, 2015: Pluristem Granted U.S. Patent for Production Methods and Use of Placental Cell Therapy in a Range of Indications
    Nov 13, 2013: Pluristem Receives Regulatory Approval to Extend Its Phase II Study of PLX-PAD Cells in the Treatment of Intermittent Claudication to South Korea
    Oct 02, 2013: Pluristem Receives Israeli Ministry of Health Approval to Expand Its Phase II Clinical Trial in Intermittent Claudication to Israel
    Sep 16, 2013: FDA Lifts Clinical Hold of Pluristem's Phase II Intermittent Claudication Study
    Jul 08, 2013: Pluristem's South Korean Partner Files IND With Korean FDA for PLX Cells
    Jun 04, 2013: Pluristem To Receive Clinical-hold Notice From FDA For US Phase II Intermittent Claudication Study
    Jan 15, 2013: Pluristem Receives Approval To Expand Phase II Clinical Trial In Intermittent Claudication To Germany
    Aug 23, 2012: Pluristem Commences Phase II Clinical Trial For Intermittent Claudication Using PLX Cells
    Aug 13, 2012: Pluristem Moves Intermittent Claudication Indication Forward in Germany Through Collaboration With Cato Research
    Jul 18, 2012: Pluristem Partners With CPC Clinical Research For Peripheral Artery Disease Study
    Apr 17, 2012: Pluristem Receives FDA Clearance For Phase II Clinical Trial In Intermittent Claudication
    Jan 11, 2012: Kowa Initiates Japan Phase IIb Clinical Trials Of Anti-Platelet Agent K-134
    Dec 02, 2011: Kowa Releases Japan Phase IIb Clinical Trials Data Of Anti-Platelet Agent, K-134
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Intermittent Claudication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Intermittent Claudication - Pipeline by Genovate Biotechnology Co LTD, H1 2017
    Intermittent Claudication - Pipeline by ID Pharma Co Ltd, H1 2017
    Intermittent Claudication - Pipeline by Kowa Company Ltd, H1 2017
    Intermittent Claudication - Pipeline by Nuo Therapeutics Inc, H1 2017
    Intermittent Claudication - Pipeline by Pluristem Therapeutics Inc, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Intermittent Claudication - Dormant Projects, H1 2017
    Intermittent Claudication - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Intermittent Claudication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Genovate Biotechnology Co LTD
    ID Pharma Co Ltd
    Kowa Company Ltd
    Nuo Therapeutics Inc
    Pluristem Therapeutics Inc

    Request for Sample

    Report Url http://www.reportsweb.com//intermittent-claudication-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//intermittent-claudication-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//intermittent-claudication-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments